Pular para o conteúdo principal
Ranking Invest

GALT - Galectin Therapeutics Inc.

Segmento: HealthcareGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Análise Ranking Invest

Valuation estimado
-16,70%
-$ 275.83 Mi
Valor de Mercado
$ 394.83 Mi
Desconto (AV)-243.1%
IVR
-0.70A companhia vale -0,70 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.35O valuation alternativo equivale a -35% do valor de mercado da companhia.
MLL
-0.35O lucro líquido dos controladores em 16 trimestres equivale a -35% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

-$ 138.57 Mi

Dívida Líquida

-$ 13.27 Mi

L4T

-$ 27.84 Mi

Indicadores Básicos

ROE

20.09%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

B0.16

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

B6.26

Margem

D0.00

Índices de Endividamento

DIV/PAT

0.10

DIV/L4T

0.48

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.